Modeling of patient virus titers suggests that availability of a vaccine could reduce hepatitis C virus transmission among injecting drug users
Marian Major(Center for Biologics Evaluation and Research), Harel Dahari(Loyola University Medical Center), Scott J. Cotler(Loyola University Medical Center), Rachel Sacks‐Davis(Burnet Institute), A. V. Kachko(Center for Biologics Evaluation and Research), Alexander Gutfraind(Chicago Department of Public Health), Kimberly Page(University of California, San Francisco), Qingwen Cui(Center for Biologics Evaluation and Research), Behzad Hajarizadeh(UNSW Sydney), Louis Shekhtman(Bar-Ilan University), Basmattee Boodram(Chicago Department of Public Health)
Cited by 46
Related Papers
The effects of female sex, viral genotype, and IL28B genotype on spontaneous clearance of acute hepatitis C virus infection
|Hepatology|2013|393
Oral prenylation inhibition with lonafarnib in chronic hepatitis D infection: a proof-of-concept randomised, double-blind, placebo-controlled phase 2A trial
|The Lancet Infectious Diseases|2015|262
Hepatitis C Treatment for Injection Drug Users: A Review of the Available Evidence
|Clinical Infectious Diseases|2009|234
Incarceration history and risk of HIV and hepatitis C virus acquisition among people who inject drugs: a systematic review and meta-analysis
|The Lancet Infectious Diseases|2018|228
A systematic examination of the use of Online social networking sites for sexual health promotion
|BMC Public Health|2011|186